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Methicillin-resistant Staphylococcus aureus (MRSA) is one of the most frequently isolated
agents in both nosocomial and community settings. It is a constant challenge for antibac-
terial therapy. Therefore, it becomes essential to understand the epidemiology of MRSA
isolates in the institution and/or region to guide empirical therapy. The objective of this study
was  to evaluate the epidemiological characteristics of MRSA isolates in the state of Santa
Catarina, Brazil, and determine if there is a clonal spread. We evaluated 124 clinical isolates
of  MRSA obtained from various anatomical sites from patients in the state of Santa Catarina
in  Southern Brazil. The antimicrobial susceptibility proﬁle was evaluated by disk diffusion
and  minimum inhibitory concentration (MIC) was determined by Etest and broth macrodi-
lution. SCCmec types were determined by multiplex PCR and the clonal relationship among
isolates was assessed by pulsed ﬁeld gel electrophoresis. Antimicrobials that have demon-
strated lower rates of resistance were tetracycline (20.2%), sulfamethoxazole–trimethoprim
(20.2%) and chloramphenicol (12.9%). We did not detect any resistance to glycopeptides,
daptomycin, linezolid, and tigecycline. SCCmec type III was predominant (54%), followed
by  type II (21.8%), consistent with other Brazilian studies. Twenty-six clones were observed
grouping 72 (58%) isolates and no clonal relationship was observed between our isolates andthe  major epidemic clones circulating in Brazil. An intriguing distinct MRSA epidemiology
was observed in Santa Catarina, compared to other Brazilian regions.
© 2015 Elsevier Editora Ltda. All rights reserved.IntroductionStaphylococcus aureus is a major agent of community-acquired
infections and healthcare associated infections. A multicenter
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1413-8670/© 2015 Elsevier Editora Ltda. All rights reserved.study among Brazilian hospitals during 2005–2008 found thatilveira).
S. aureus was the main agent of bloodstream infections (20.2%)
and infections of the skin and soft tissue (28.1%) and the
second most common agent in pneumonia of hospitalized
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atients (24.9%). Of these infections, approximately 30% were
esistant to methicillin (MRSA).1
Staphylococci become resistant to methicillin by changing
ranspeptidases in the wall, called penicillin-binding proteins
PBPs), and lose afﬁnity for all -lactam agents. This informa-
ion is contained in the mecA gene responsible for encoding
n altered PBP (PBP2a).2,3
Until the early 1990s, MRSA isolates were restricted to
ospitals. Currently, however, MRSA is no longer exclusively
ssociated with healthcare infections. During this period,
ncrease in community-acquired MRSA (CA-MRSA) among
atients without assignable risk factors for acquiring MRSA
as observed (i.e., had no direct or indirect contact with health
ervices that could associate the MRSA infection with health
are) .4
Since then, a reverse phenomenon began to occur: com-
unity isolates, once characterized by the presence of a
taphylococcal cassette chromosome (SCCmec) type IV, began
o be isolated in hospital settings and those types that
ere typically isolated in the hospital began to appear in
utpatients.5,6
As the epidemiology of MRSA proved to be dynamic, it is
mportant to generate data to better understand the evolution
f this epidemiological behavior and to assess its impact on
linical settings.7 Santa Catarina State has an intriguing low
revalence of MRSA compared to other Brazilian States and
nderstand this epidemiological dynamics would be valuable.
The objective of this study was to evaluate the epidemio-
ogical characteristics of MRSA isolates in the state of Santa
atarina.
ethods
acterial  samples
e  used 124 clinical MRSA isolates obtained from various
natomical sites from patients attended in two cities (Blume-
au and Florianopolis), located in the State of Santa Catarina,
outhern Brazil. Samples were collected from November
009 through February 2013. One isolate per patient was
onsidered. Samples were selected by convenience. Identiﬁca-
ion was done using standardized phenotypic methodology8
nd isolates were maintained frozen (−20◦ C) in skim milk
DIFCO®) plus 10% glycerol.
ntimicrobial  susceptibility  testing
ntimicrobial susceptibility testing was performed using the
isk diffusion method, according to the recommendations
nd interpretative criteria of the Clinical and Laboratory
tandards Institute9 and European Committee on Antimi-
robial Susceptibility Testing (to tygecycline only).10 The
ntimicrobials tested were gentamicin (10 g), ciproﬂoxacin
5 g), erythromycin (15 g), clindamycin (2 g), trimetho-
rim/sulfamethoxazole (1.25 g/23.75 g), chloramphenicol
30 g), tetracycline (30 g), teicoplanin (30 g), tigecycline
10 g), and linezolid (30 g). MRSA was characterized using
he cefoxitin disk (30 g), and conﬁrmed by PCR for the gene
ecA.11 To detect -lactamase production, we  used nitroceﬁn5;1 9(4):384–389 385
disk (BD BBLTM DrySlideTM Nitroceﬁn), using bacterial suspen-
sions in physiological saline. S. aureus ATCC 29213 was used
as a positive control, and S. aureus ATCC 25923 was used as a
negative control.
MIC  determination
Vancomycin MICs were determined by  macrodilution
method9 and by Etest® (BioMérieux, Marcy  l’Etoile, France)
following CLSI interpretative criteria9 and the manufacturer’s
instructions, respectively. MICs for teicoplanin and dapto-
mycin were determined by Etest®. S. aureus strains ATCC
29213 (MSSA), ATCC 43300 (MRSA), ATCC 700698 (hVISA) and
ATCC 700699 (VISA) were used for quality control.
Multiplex  PCR
The SCCmec type was determined using the multiplex PCR
method according to the protocol developed by Zhang et al.12
The amplicons that were formed had the following sizes: I
(613 bp), II (398 bp), III (280 bp), IVa (776 bp), IVb (493 bp), IVc
(200 bp), IVd (881 bp), and V (325 bp).12,13
For isolates presenting phenotypic inducible resistance to
clindamycin, erm gene was assessed by a multiplex PCR proto-
col, described elsewhere.14 The PCR product (610 bp for ermA
and 520 bp for ermC) was analyzed by electrophoresis through
a 1.5% agarose gel.14,15
Pulsed-ﬁeld  gel  electrophoresis  (PFGE)
PFGE was performed according to McDougal et al.16 and Pinto
et al.17 The fragments were subjected to PFGE using 1%
agarose gels (Pulsed Field Certiﬁed Agarose; Bio-Rad) in 0.5×
Tris–borate–EDTA buffer with a CHEF-DR III system (Bio-Rad).
Gels were stained with 0.5 g/mL ethidium bromide, visu-
alized under UV light, and photographed using a GelDocTM
XR System (Bio Rad). PFGE patterns were analyzed using
Bionumerics version 6.1 (Applied Maths, Sint-Martens-Latem,
Belgium) and clustered by UPGMA. A dendrogram was gen-
erated from a similarity matrix calculated using the Dice
similarity coefﬁcient with an optimization of 0.5% and a tol-
erance of 1%. PFGE clusters were deﬁned as isolates with a
similarity of 80% or higher on the dendrogram.18 SCCmec  con-
trol strains were included [type I (NCTC10442); type II (N315);
type III (85/2082); type IVa (CA05); type IVb (8/6-3P); type IVc
(MR108); type IVd (JSC4469) and type V (WIS)], as well as iso-
lates of the main circulating epidemic clones in Latin America
(Brazilian Epidemic Clone, New York/Japan, USA300, USA400,
Pediatric, OSPC, Cordobean, E-MRSA 15, E-MRSA 16).
Results
MRSA isolates were recovered mainly from lower respira-
tory tract samples (37.1%), followed by clinical osteomyelitis
cases (19.4%), blood (13.7%), surgical wounds (9.7%), urine (4%),
and abscesses (3.2%). In addition, 1.6% of MRSA were from
surveillance cultures, and 11.3% were recovered from other
anatomical sites. Considering the origin of the samples, 17
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Fig. 1 – MIC  of the glycopeptides to 124 MRSA determined by Etest. In (A), the values obtained for vancomycin. The seven
isolates with MIC  of 3.0 g/mL were  considered susceptible because all MICs were  ≤2.0 g/mL by microdilution. In (B), the
ted bresults for teicoplanin. One isolate (MIC 12 g/mL) when tes
(13.7%) were considered community isolates and 107 (86.3%)
hospital isolates.
MRSA presented the following resistance rates: amikacin
(35.5%), gentamicin (33.1%), chloramphenicol (12.9%), tetra-
cycline (20.2%), ciproﬂoxacin (79%), norﬂoxacin (72.6%),
sulfamethoxazole–trimethoprim (20.2%), clindamycin (75%),
and erythromycin (81.5%). Also, 93 strains (75%) showed
production of -lactamase. All isolates were susceptible to
linezolid and tigecycline.
All isolates were susceptible to vancomycin and MICs are
presented in Fig. 1. Seven isolates showed MIC  of 3.0 g/mL by
Etest. By macrodilution three of them showed MIC of 1.0 g/mL
and four had MIC  of 2.0 g/mL. Etest also overestimated (above
CLSI susceptibility breakpoint) teicoplanin MIC for one isolate
but macrodilution deﬁned its MIC  as 4 g/mL (susceptible by
CLSI interpretative criteria).
Daptomycin, an alternative to glycopeptides for the treat-
ment of infections caused by MRSA, showed MCI values within
the susceptibility range (Fig. 2), even though four isolates
presented MIC  of 1.0 g/mL (upper limit of susceptibility cate-
gory).
Although predominant SCCmec was type III (54%, 67/124),
there was a heterogeneous distribution of SCCmec types: type
II (21.8%), type IVa (10.5%), type IVc (3.2%) and type IVb (2.4%).
Five isolates carried types I and II together. Among CA-MRSA
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Fig. 2 – MICs for daptomycin determined by Etest. All
isolates were  considered susceptible (MIC ≤ 1.0 g/mL).y microdilution yielded an MIC  of 4.0 g/mL (susceptible).
(n = 17), only four showed SCCmec type IV: two IVa and two  IVb.
Among the other 13 isolates, eight had SCCmec type III and ﬁve
had type II.
Of the 124 isolates, 23 (18.5%) had a positive D test: 20 (87%)
had ermA gene and three (13%) carried ermC. Twelve (9.7%)
isolates presented resistance to erythromycin and suscepti-
bility to clindamycin (negative D test) and had no positive PCR
reaction. Fifty-six (45.1%) isolates have had constitutive resis-
tance mechanism and only 33 (26.6%) were susceptible to both
antibiotics.
Twenty-six clones (Fig. 3) were observed, grouping 72 iso-
lates (with ﬁve being the highest number of isolates per clone).
Indeed, 52 isolates presented a unique pulsotype. Isolates
belonging to all clones carried SCCmec type III (Table 1).
Discussion
The prevalence of MRSA in the state of Santa Catarina is
extremely low and is comparable to rates found in Scandi-
navian countries.2,19,20 Isolation rates are in the range of 4–8%
for all isolated S. aureus and these rates are even lower when
only nosocomial isolates are considered (less than 2%). Such
low occurrence of MRSA justiﬁes the intriguing low number of
MRSA included in this study, as the two most populous cities
of Santa Catarina were included. In a report published by the
World Health Organization (WHO), several European countries
have national surveillance data with very low rates of MRSA:
Denmark (1.2%), Estonia (1.7%), Finland (2.8%), Iceland (2.8%),
Netherlands (1.4%), Norway (0.3%) and Sweden (0.8%).21 These
countries may have succeeded in maintaining low MRSA rates
because of effective search-and-destroy policies and/or con-
trolled antibiotic overuse.22 Of note, occurrence of MRSA in
Santa Catarina differs greatly from other regions of Brazil,
which have, in general, MRSA rates of around 29%.23,24 As far
as we know, those search-and-destroy policies are not prac-
ticed in Santa Catarina and, surprisingly, MRSA isolation rates
are similar to those found in the Scandinavian countries.
There was a predominance of isolates from lower res-
piratory tract infections, osteomyelitis, and bloodstream
infections. These data are quite distinct from those found in
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Fig. 3 – Dendrogram illustrating the PFGE patterns of 124
strains and controls. Twenty-six clones were  observed.5;1 9(4):384–389 387
studies with similar characteristics, which demonstrate a pre-
dominance of bloodstream infections (39%)25 or skin and soft
tissue infections (61.5%).26
Compared to the antimicrobial surveillance in the mul-
ticenter study SENTRY,1 resistance rates in this study
were much lower: ciproﬂoxacin (91.4–79%), tetracycline
(46.7–20.2%), trimethoprim–sulfamethoxazole (68.1–20.2%),
clindamycin (87.9–75%) and erythromycin (94–81.5%). A pos-
sible explanation for the large differences in rates of
susceptibility could be due to the epidemiological proﬁle.
Cavalcante et al. proposed phenotypic markers associ-
ated with SCCmec types. Resistance to tetracycline and
trimethoprim–sulfamethoxazole may be associated with
SCCmec type III, in which 100% resistance was found to both
drugs. SCCmec type IV had absolute susceptibility, with only
2% of the isolates resistant to trimethoprim–sulfamethoxazole
and 100% susceptibility to tetracycline.27 We found a predom-
inance of SCCmec type III, which justiﬁes why the resistance
rates in our study were lower than those found in the rest of
Brazil.
The presence of -lactamase may result in unusual phe-
notypes known as BORSA (Borderline Oxacillin Resistant S.
aureus). These bacteria, despite lacking the mecA gene, may
be resistant to oxacillin and are phenotypically character-
ized as MRSA.28 They may also be responsible for elevated
MICs of oxacillin. After therapy with -lactams, these bacte-
ria may induce the development of vancomycin resistance,
a phenotype called -lactam antibiotics-induced vancomycin
resistant S. aureus (BIVR).29
All MRSA were susceptible to vancomycin, teicoplanin and
daptomycin. Although the phenotype of resistance to these
drugs is uncommon.30 31.45% of the isolates showed MIC
of 2.0 g/mL for vancomycin, which may suggest the devel-
opment of a phenomenon of an upward trend for MICs for
vancomycin, called “MIC creep”.31
The isolates demonstrated higher prevalence of gene ermA
than ermC. The D test proved to be a methodology capable of
detecting all isolates with inducible clindamycin resistance.
Therefore, the test is easy to perform, inexpensive and is clin-
ically relevant because it reduces the risk of inappropriate
antibiotics use.32
In our study, there was a high prevalence of SCCmec  type III
(54%). In 2010, a study conducted at the Hospital de Clinicas de
Porto Alegre (capital of the neighboring state of Rio Grande do
Sul), a high prevalence of SCCmec type III was detected (49%),33
similar to our ﬁndings. In 2005, in contrast to the local epi-
demiology, a study conducted at the Hospital de Clinicas de
São Paulo found that 65% of MRSA carried SCCmec type IV.34
Not surprising, our isolates did not present a clonal dis-
semination, as both cities (Florianopolis and Blumenau) are
separated by approximately 120 km and the isolates were col-
lected during a period of three years.
Interestingly, we  did not ﬁnd clonal relationship between
our isolates and the major circulating epidemic clones in
Brazil, which may suggest that the state of Santa Catarina has
different epidemiological characteristics compared to other
regions in the country. Surveillance studies must be con-
tinuously conducted to better understand epidemiological
dynamics of such a clinically relevant microorganism.
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Table 1 – Epidemiological and antibiotic susceptibility characteristics of the 26 clones.
Clones Isolates Time Source City Resistance SCCmec
1 SI2, SI8 2–4/09 HOS BLU ER, CL, SU, CIP, N0, TE, CLO, AM, GE II
2 SI10, SI29, L79 5/09–1/12 HOS BLU, FLO ER, CL, CIP, NO II
3 L35, L77 9/10–12/11 HOS FLO ER, CL, CIP, NO II
4 SI3, SI14 2/09–4/10 COM BLU ER, CL, CIP, NO II
5 SI15, SI30 4/10–1/12 HOS BLU ER, CL, CIP, NO II
6 SI1, SI5, SI9, L58, L86 1/09–3/12 HOS BLU, FLO ER, CL, CIP, NO III
7 L40, L61, L62 10/10–4/11 HOS FLO ER, CL, CIP, NO II
8 SI16, SI28, L72 5/10–11/11 HOS BLU, FLO CIP, NO IVa
9 L22, L32, L46, L49, L81 7/10–1/12 HOS FLO ER, CL, CIP, NO III
10 L39, L47, L48 8/10–11/10 HOS FLO ER, CL, CIP, NO III
11 L55, L66, L88 6/11–5/12 HOS FLO ER, CL, CIP, NO III
12 SI25, L27, L94 2/10–10/12 COM, HOS BLU, FLO ER, CL, CIP, NO IVa
13 L5, L75 8/08–11/11 COM, HOS FLO – IVa
14 L19, L25, L59 7/10–2/11 HOS FLO ER, CL, CIP, NO IVa
15 L91, L93 7/12–10/12 HOS FLO ER, CL, CIP, NO IVb
16 L20, L50 7/10–11/10 HOS FLO ER, CL, SU, CIP, NO, AM. GE III
17 L24, L26, L28, L29 7/10–8/10 HOS FLO ER, CL, CIP, NO, AM, GE I
18 L12, L21, L70 12/09–6/11 HOS FLO ER, CL, CIP, NO, CLO, AM, GE III
19 L13, L14, L17 1/10–5/10 COM, HOS FLO ER, CL, SU, CIP, NO, TE, AM, GE III
20 L3, L6 7/08–1/09 HOS FLO ER, CL, SU, CIP, NO, TE, CLO, AM, GE III
21 L43, L51 10/10–11/10 HOS FLO ER, CL, SU, CIP, NO. AM. GE III
22 SI19, L67 8/10–1/11 COM, HOS BLU, FLO ER, CL, CIP, NO III
23 L2, L4 5/08–6/08 COM, HOS FLO – IVa
24 L44, L63 10/10–7/11 HOS FLO ER, CL, CIP, NO, AM, GE III
25 L54, L69, L92 5/11–8/12 HOS FLO ER, CL, SU, CIP, NO, TE, CLO, AM, GE II
26 L36, L41, L42, L80 9/10–1/12 HOS FLO ER, CL, CIP, NO II
 ER, e
nicol
rHOS, hospital; COM, community; BLU, blumenau; FLO, ﬂorianopolis;
CIP, ciproﬂoxacin; NO, norﬂoxacin; TE; tetracycline; CLO, chloramphe
Conclusions
Although we identiﬁed the SCCmec that were present and eval-
uated the presence of clones, the present study did not provide
consistent scientiﬁc evidence for the low prevalence of MRSA
in Santa Catarina, which was very different from the data
found in other Brazilian states and some European countries.
We conclude that the MRSA epidemiological proﬁle in
Santa Catarina is similar to that found in the rest of Brazil,
with a predominance of SCCmec type III, but the resistance
rates were lower than those found in the rest of Brazil.
A wide variety of complexes with clonal isolates were
detected without evidence of clonal spread, and a small
amount of high genetic diversity was found.
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